BioGrowing, a global probiotics comprehensive solutions provider, concluded its successful participation as a General Partner at Pharmtech & Ingredients 2025, held from November 25–28 at Moscow’s Crocus Expo. The company showcased its latest advancements in probiotics research and application, with a highlight on groundbreaking innovations such as the Akkermansia muciniphila double star strains and BioGuard® Starter Cultures, attracting significant attention from global industry professionals.
At the core of BioGrowing’s exhibition were two innovative Akkermansia muciniphila strains. Akkermansia muciniphila is a next-generation probiotic strain demonstrating exceptional potential in gut health innovation.
Akkermansia muciniphila WST01, a clinically validated live strain, has demonstrated remarkable efficacy in a 12-week randomized, double-blind, placebo-controlled trial involving overweight/obese type 2 diabetics, showing significant reductions in body weight, BMI, HbA1c, visceral fat mass, and LDL-C, etc., while enhancing insulin sensitivity and fat oxidation rates. The related research is published in Cell Metabolism.
Akkermansia muciniphila WST01 achieved Self-GRAS status and patents across 13 countries and regions.
AKKBG-001TM is an heat-killed strain sourced from healthy human intestines origins in Kashgar, Xinjiang, produced by BioGrowing’s proprietary anaerobic fermentation and high-fidelity inactivation. This postbiotic exhibits high tolerance to heat, acid, and oxygen, enabling versatile applications in functional foods and beverages.
Both Akkermansia muciniphila strains have achieved mass production. The company featured its 30 billion TFU high-purity AKKBG-001™ capsules at the booth, synergized with EGCG and vitamins, offering a scalable solution for weight management.
As a leading global starter cultures provider, BioGrowing underscores its expertise in delivering BioGuard® Starter Cultures,—evaluated rigorously across six core performance dimensions: high fermentation activity, post-acidity stability, smooth texture, unique aroma, good water retention, and anti-phage capabilities. Its comprehensive product portfolio spans multiple application-focused categories, including thermophilic dairy starter cultures, mesophilic dairy starter cultures, drinking beverage starter cultures, plant-based starter cultures, and biological protective cultures—catering to diverse formulation needs across the food and beverage sectors and the increasing demand for clean labels.
BioGrowing’s starter cultures are developed based on nearly 20 years of foundational research and large-scale production experience. The company’s solutions are already trusted by clients worldwide, including leading global dairy groups ranked among the Global TOP 500, reflecting its capacity to meet the stringent requirements of international, industrial partnerships.
Also, BioGrowing highlighted its Flora-Focus® series, covering nine health domains including gut health, immune support, oral health and more. The GRAS-certified Weizmannia coagulans BC-G44 stood out for its stability and efficacy in immune and digestive applications. Additionally, innovations like OralBubble™ Probiotic Microbubble Lozenge and OralFlashTM Flash-Melt probiotics underscored the company’s focus on providing adaptable, consumer-friendly application solutions.
BioGrowing was recognized by Lumina Intelligence as one of the TOP 3 immune probiotic and TOP 5 digestive probiotic suppliers. With over 20 years of specialized experience and exports to more than 80 countries and regions, the market recognition is supported by a culture collection of over 50,000 strains—a testament to its scientific legacy and commitment to microbial research and development.
With over 20 years of expertise and a repository of 50,000+ proprietary strains, BioGrowing has exported to 80+ countries, earning recognition as a Top 3 immune health and Top 5 digestive probiotic supplieracross APAC. Dr. Guo Peng, Chief Technology Officer, emphasized: "Our solutions bridge clinical research and commercial scalability, empowering our partners to meet localized health demands effectively."
BioGrowing’s participation at Pharmtech & Ingredients 2025 reinforced its role as a leader in probiotic innovation. By integrating advanced research with practical applications, the company continues to drive sustainable industry growth and global health advancements.
About BioGrowing
BioGrowing Co., Ltd. is a probiotics comprehensive solution provider focused on the research, development, production and sales of high-quality probiotic products. As one of the largest probiotic production bases in Asia, the company offers a product range covering probiotic powders, starter cultures, functional foods, and derivative products which are widely used in food, medicine and healthcare, daily chemicals, aquaculture, and many other fields. BioGrowing maintains a repository of over 50,000 probiotic strains, each with independent intellectual property rights. The products have been successfully exported to over 80 countries, including 22 out of the 27 EU member nations. With "BioGrowing, Reliable for a Better World" as its core value, BioGrowing is committed to probiotics' research, development, and innovation, moving continuously towards the vision of a "global leading probiotics manufacturer" and providing customers with a full range of product solutions and high-quality services.
